Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

Science

Volumn 351, Issue 6279, 2016, Pages 1339-1342

  Corti, Davide ^a,b   Misasi, John ^c   Mulangu, Sabue ^c   Stanley, Daphne A ^c   Kanekiyo, Masaru ^c   Wollen, Suzanne ^d   Ploquin, Aurélie ^c   Doria Rose, Nicole A ^c   Staupe, Ryan P ^c   Bailey, Michael ^c   Shi, Wei ^c   Choe, Misook ^c   Marcus, Hadar ^c   Thompson, Emily A ^c   Cagigi, Alberto ^c   Silacci, Chiara ^a   Fernandez Rodriguez, Blanca ^a   Perez, Laurent ^a   Sallusto, Federica ^a   Vanzetta, Fabrizia ^b   Agatic, Gloria ^b   Cameroni, Elisabetta ^b   Kisalu, Neville ^e   Gordon, Ingelise ^c   Ledgerwood, Julie E ^c   Mascola, John R ^c   Graham, Barney S ^c   Muyembe Tamfun, Jean Jacques ^e   Trefry, John C ^d   Lanzavecchia, Antonio ^a,f   Sullivan, Nancy J ^c   more..

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^b Humabs BioMed SA ^*  (Switzerland)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^e National Laboratory of Public Health   (Democratic Republic Congo)

^f ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 100; MONOCLONAL ANTIBODY 114; MONOCLONAL ANTIBODY 13C6; MONOCLONAL ANTIBODY 165; MONOCLONAL ANTIBODY 166; MONOCLONAL ANTIBODY KZ52; UNCLASSIFIED DRUG; ZMAPP; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY; DISEASE SPREAD; HOMINID; MORTALITY; POPULATION OUTBREAK; PROTEIN; SURVIVAL; TOXICITY; VACCINE; VIRAL DISEASE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; ARTICLE; DRUG ISOLATION; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EFFECTOR CELL; EPIDEMIC; HUMAN; MACACA; MACROPHAGE; MEMORY CELL; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; SOMATIC MUTATION; VIRAL CLEARANCE; ADULT; ANIMAL; CLINICAL TRIAL (TOPIC); FEMALE; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MOLECULAR GENETICS; SURVIVOR;

EBOLA VIRUS; MACACA;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA; MALE; MOLECULAR SEQUENCE DATA; SURVIVORS;

EID: 84959359636     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aad5224     Document Type: Article

References (20)

1. WHO Ebola Response Team, N. Engl. J. Med. 371, 1481-1495 (2014).
2. J. Burke, R. Declerq, G. Ghysebrechts, Bull. World Health Organ. 56, 271-293 (1978).
3. A. Gulland, BMJ 350, h1619 (2015).
4. J. J. Muyembe-Tamfum etal., Onderstepoort J. Vet Res. 79, 451 (2012).
5. X. Qiu et al., Clin. Immunol. 141, 218-227 (2011).
6. J. A. Wilson et al., Science 287, 1664-1666 (2000).
7. X. Qiu et al., Nature 514, 47-53 (2014).
8. J. J. Muyembe-Tamfun, M. Kipasa, C. Kiyungu, R. Colebunders, J. Infect. Dis. 179(suppl. 1), S259-S262 (1999).
9. See supplementary materials on Science Online.
10. E. Traggiai et al., Nat. Med. 10, 871-875 (2004).
11. T. Maruyama et al., J. Virol. 73, 6024-6030 (1999).
12. M. Côté et al., Nature 477, 344-348 (2011).
13. L. Pappas et al., Nature 516, 418-422 (2014).
14. D. H. Barouch et al., Nature 503, 224-228 (2013).
15. J. E. Lee et al., Nature 454, 177-182 (2008).
16. C. D. Murin et al., Proc. Natl. Acad. Sci. U. S. A. 111, 17182-17187 (2014).
17. G. G. Olinger Jr. et al., Proc. Natl. Acad. Sci. U. S. A. 109, 18030-18035 (2012).
18. M. Hezareh, A. J. Hessell, R. C. Jensen, J. G. van de Winkel, P. W. Parren, J. Virol. 75, 12161-12168 (2001).
19. W. B. Oswald et al., PLOS Pathog. 3, e9 (2007).
20. J. Misasi et al., Science 351, 1343-1346 (2016).